Effects of parecoxib on the prevention of postoperative peritoneal adhesions in rats.
BACKGROUND
No systemic preventive therapy has been successful in inhibiting the development of postoperative peritoneal adhesions (PPAs).


OBJECTIVE
The aim of this study was to evaluate the potential effects of 5 day administration of parecoxib, on PPA prevention and on suture or wound healing in rats.


METHODS
In a model of PPAs induced by peritoneal electrical burn, 30 rats were randomized into 3 groups according to parecoxib administration route (control; intraperitoneal (IP); intramuscular (IM)). Plasma and peritoneal levels of PAI-1 and tPA were measured at T0, after 90 min of surgery (T90), and on postoperative day 10 (D10). In a cecum resection model, 20 rats were randomized into two groups (control and IP parecoxib), and abdominal wound healing and suture leakage were assessed at D10. In both models, PPAs were evaluated quantitatively and qualitatively on D10.


RESULTS
Administration of parecoxib significantly decreased the quantity (p < .05) and the severity (p < .01) of PPAs in both models. In addition, parecoxib administration did not cause healing defects or infectious complications in the two models. In the peritoneal burn model, IP or IM parecoxib administration inhibited the increase of postoperative plasma and peritoneum PAI-1 levels, an increase that was observed in the control group (p < .01). No anastomosis leakage could be demonstrated in both groups in the cecum resection model.


CONCLUSIONS
This study showed that, in these rat models, parecoxib might reduce PPA formation. Confirmation of the safety of parecoxib on intestinal anastomoses is required and should be investigated in further animal models.
1 Centre de Recherche et Développement en Chirurgie (CREDEC), GIGA- Cardiovascular Sciences, University of Liege (ULg), Liege, Belgium.
Willy
W
Arung
François
F
Jehaes
Jean-Paul
JP
Cheramy
Jean-Olivier
JO
Defraigne
Michel
M
Meurisse
Pierre
P
Honoré
Pierre
P
Drion
Olivier
O
Detry
D000714:Anastomosis, Surgical / Q000379:methods; D000818:Animals; D002058:Burns, Electric / Q000188:drug therapy; D002432:Cecum / Q000601:surgery; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D007273:Injections, Intramuscular; D007555:Isoxazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D010532:Peritoneal Diseases / Q000517:prevention & control*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D011183:Postoperative Complications / Q000517:prevention & control; D051381:Rats; D017207:Rats, Sprague-Dawley; D000267:Tissue Adhesions / Q000517:prevention & control; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D014945:Wound Healing / Q000187:drug effects
D052246:Cyclooxygenase 2 Inhibitors; D007555:Isoxazoles; D017395:Plasminogen Activator Inhibitor 1; C409945:parecoxib; D010959:Tissue Plasminogen Activator